ARGO trial Ph 2 RCT Sonelokimab IL-17A/Fi Nanobody Wk 12, primary ACR50 ACR 50 SON 120 mg 46% 60 mg 46% PBO 20% PASI 90
Tweet Content
ARGO trial Ph 2 RCT Sonelokimab IL-17A/Fi Nanobody
Wk 12, primary ACR50
ACR 50 SON 120 mg 46% 60 mg 46% PBO 20%
PASI 90 SON 120 mg 60% 60 mg 77% PBO 15%
MDA SON 60mg 47% PBO 20%
No new safety signal
#EULAR2024 @RheumNow AbstrOP0195 https://t.co/4W5KFi23za
Show on Archive Page
On
Display in Search Results
On
PDQ
Off